COVID-19 与凝血功能障碍。
COVID-19 and coagulopathy.
机构信息
Department of pulmonary medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
Department of Medical and Pediatric Oncology, Kerudi Cancer Hospital, Bagalkot, Karnataka, India.
出版信息
Clin Respir J. 2021 Dec;15(12):1259-1274. doi: 10.1111/crj.13438. Epub 2021 Aug 30.
Abstract
The SARS-CoV-2 is a new coronavirus responsible for the COVID-19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID-19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID-19 patients such as inflammation, endotheliitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE, and CINAHL from January 2020 to December 2020. We used the following search terms: COVID-19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID-19-associated coagulopathy.
摘要
SARS-CoV-2 是一种新型冠状病毒，可引发 COVID-19 疾病，并在全球范围内引发大流行。大量病例使全球医疗系统不堪重负。COVID-19 感染与血栓栓塞并发症的风险增加有关。多种机制导致 COVID-19 患者存在高血栓形成风险，如炎症、血管内皮炎、高黏滞血症和高凝状态。我们检索了 2020 年 1 月至 12 月期间的 PubMed、EMBASE 和 CINAHL，使用了以下检索词：COVID-19、凝血障碍和血栓形成。我们回顾了 COVID-19 相关凝血障碍的流行病学、临床特征、机制和治疗方法。
相似文献
1
COVID-19 and coagulopathy.COVID-19 与凝血功能障碍。
Clin Respir J. 2021 Dec;15(12):1259-1274. doi: 10.1111/crj.13438. Epub 2021 Aug 30.
2
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.COVID-19 的凝血功能障碍、血管内皮功能障碍和血管炎。
Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12.
3
Coagulopathy in COVID-19 and anticoagulation clinical trials.新型冠状病毒肺炎合并凝血病与抗凝临床试验
Best Pract Res Clin Haematol. 2022 Sep;35(3):101377. doi: 10.1016/j.beha.2022.101377. Epub 2022 Aug 23.
4
[COVID-19-associated coagulopathy].[新型冠状病毒肺炎相关凝血病]
Rinsho Ketsueki. 2021;62(8):1236-1246. doi: 10.11406/rinketsu.62.1236.
5
Malignant Cerebral Ischemia in A COVID-19 Infected Patient: Case Review and Histopathological Findings.COVID-19 感染患者的恶性大脑缺血：病例回顾与组织病理学发现。
J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105231. doi: 10.1016/j.jstrokecerebrovasdis.2020.105231. Epub 2020 Aug 5.
6
Clinical Features and Management of COVID-19-Associated Hypercoagulability.新型冠状病毒病相关高凝血症的临床特征和处理。
Card Electrophysiol Clin. 2022 Mar;14(1):41-52. doi: 10.1016/j.ccep.2021.10.005. Epub 2021 Oct 30.
7
COVID-19 Coagulopathy: From Pathogenesis to Treatment.COVID-19 凝血功能障碍：从发病机制到治疗。
Acta Haematol. 2022;145(3):282-296. doi: 10.1159/000522498. Epub 2022 Feb 8.
8
COVID-19-associated coagulopathy.新型冠状病毒肺炎相关凝血病
Diagnosis (Berl). 2020 Nov 18;7(4):357-363. doi: 10.1515/dx-2020-0078.
9
Current Overview on Hypercoagulability in COVID-19.新型冠状病毒肺炎患者高凝状态的研究现状。
Am J Cardiovasc Drugs. 2020 Oct;20(5):393-403. doi: 10.1007/s40256-020-00431-z.
10
Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019.2019 年冠状病毒病中涉及血小板活化、高凝状态和纤溶活性降低的血栓形成机制。
Int J Mol Sci. 2023 Apr 28;24(9):7975. doi: 10.3390/ijms24097975.
引用本文的文献
1
Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China.低分子量肝素在COVID-19住院患者中预防静脉血栓栓塞的真实世界实践：一项来自中国的多中心前瞻性研究。
Thromb J. 2025 Jun 20;23(1):69. doi: 10.1186/s12959-025-00741-9.
2
Unfolded von Willebrand factor binds protein S and reduces anticoagulant activity.未折叠的血管性血友病因子结合蛋白S并降低抗凝活性。
Blood Vessel Thromb Hemost. 2025 Feb;2(1). doi: 10.1016/j.bvth.2024.100030. Epub 2024 Sep 25.
3
A nomogram based on the TyG index for the prediction of lower-limb venous thrombosis in patients with intracerebral hemorrhage.基于TyG指数的脑出血患者下肢静脉血栓形成预测列线图。
Sci Rep. 2025 May 19;15(1):17406. doi: 10.1038/s41598-025-01923-1.
4
Hereditary thrombophilia as a possible risk factor for severe disease in COVID-19: a case series.遗传性血栓形成倾向作为COVID-19严重疾病的可能危险因素：病例系列
Forensic Sci Med Pathol. 2025 Mar;21(1):260-266. doi: 10.1007/s12024-024-00879-4. Epub 2024 Sep 27.
5
Management of COVID-19 in Ophthalmology.眼科 COVID-19 管理。
Adv Exp Med Biol. 2024;1457:401-429. doi: 10.1007/978-3-031-61939-7_23.
6
The Impact of Cytokines on Coagulation Profile in COVID-19 Patients: Controlled for Socio-Demographic, Clinical, and Laboratory Parameters.细胞因子对COVID-19患者凝血谱的影响：对社会人口统计学、临床和实验室参数进行了控制。
Biomedicines. 2024 Jun 10;12(6):1281. doi: 10.3390/biomedicines12061281.
7
The role of IL-6, ferritin, and coagulopathy in Covid-19 clinical progression.IL-6、铁蛋白和凝血功能障碍在新冠肺炎临床进展中的作用。
F1000Res. 2023 Sep 22;11:1285. doi: 10.12688/f1000research.125115.2. eCollection 2022.
8
The Prevalence of Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎患者胃肠道出血的发生率：系统评价和荟萃分析。
Medicina (Kaunas). 2023 Aug 21;59(8):1500. doi: 10.3390/medicina59081500.
9
COVID-19 HEART unveiling as atrial fibrillation: pathophysiology, management and future directions for research.COVID-19引发的心脏问题表现为心房颤动：病理生理学、管理及未来研究方向
Egypt Heart J. 2023 Apr 30;75(1):36. doi: 10.1186/s43044-023-00359-0.
10
Gastrointestinal Bleeding in COVID-19-Infected Patients.新冠病毒感染患者的胃肠道出血。
Gastroenterol Clin North Am. 2023 Mar;52(1):77-102. doi: 10.1016/j.gtc.2022.10.004. Epub 2022 Nov 1.
本文引用的文献
1
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
2
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.美国血液学会 2021 年关于 COVID-19 患者抗凝血栓预防治疗的指南。
Blood Adv. 2021 Feb 9;5(3):872-888. doi: 10.1182/bloodadvances.2020003763.
3
Acute Ischemic Stroke in COVID-19: A Case-Based Systematic Review.COVID-19相关急性缺血性卒中：一项基于病例的系统评价
Front Neurol. 2020 Sep 25;11:1031. doi: 10.3389/fneur.2020.01031. eCollection 2020.
4
Immune-Mediated Coagulopathy in COVID-19 Infection.新型冠状病毒肺炎感染中的免疫介导性凝血病
Semin Thromb Hemost. 2020 Oct;46(7):838-840. doi: 10.1055/s-0040-1714272. Epub 2020 Sep 2.
5
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19.COVID-19 住院患者的抗凝、出血、死亡率和病理学。
J Am Coll Cardiol. 2020 Oct 20;76(16):1815-1826. doi: 10.1016/j.jacc.2020.08.041. Epub 2020 Aug 26.
6
Impact of COVID-19 on monitoring of therapeutic unfractionated heparin.2019冠状病毒病对普通肝素治疗监测的影响
J Thromb Thrombolysis. 2021 Apr;51(3):827-829. doi: 10.1007/s11239-020-02250-0.
7
Postdischarge venous thromboembolism following hospital admission with COVID-19.COVID-19 住院后出院后的静脉血栓栓塞症。
Blood. 2020 Sep 10;136(11):1347-1350. doi: 10.1182/blood.2020008086.
8
Mechanisms of Stroke in COVID-19.新冠病毒感染所致中风的机制
Cerebrovasc Dis. 2020;49(4):451-458. doi: 10.1159/000509581. Epub 2020 Jul 20.
9
Prevalence and Outcomes of Acute Ischemic Stroke Among Patients ≤50 Years of Age With Laboratory Confirmed COVID-19 Infection.实验室确诊的 COVID-19 感染的 50 岁及以下患者中急性缺血性卒中的患病率和结局
Am J Cardiol. 2020 Sep 1;130:169-170. doi: 10.1016/j.amjcard.2020.06.010. Epub 2020 Jun 14.
10
COVID-19-associated coagulopathy-Hypothesis: Are children protected due to enhanced thrombin inhibition by higher α -Macroglobulin macroglobulin (α2-M)?新型冠状病毒肺炎相关凝血病——假说：儿童是否因较高的α2-巨球蛋白（α2-M）增强凝血酶抑制作用而受到保护？
J Thromb Haemost. 2020 Sep;18(9):2416-2418. doi: 10.1111/jth.15013.
Zotero 插件